What Endevica Bio does

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide therapeutics that target the melanocortin system (MC3R/MC4R receptors) to treat metabolic diseases. The company is headquartered in Northbrook, Illinois (incorporated in Delaware), was founded in 2009, and operates with a small, focused team of 11–50 chemists, biologists, and computational chemists. Its proprietary peptidomimetics platform designs peptides capable of crossing the blood-brain barrier to modulate central melanocortin receptors, exploiting the discovery that TCMCB07 is transported by a multi-specific bile salt carrier — a technically demanding capability that distinguishes the platform from conventional CNS-targeted approaches.

The company's pipeline comprises two clinical-stage drug candidates. TCMCB07 (mifomelatide) is a dual MC3R/MC4R antagonist peptide currently in a Phase 2 trial (NCT06937177) for preventing weight loss and cachexia in patients with stage 4 metastatic colorectal cancer undergoing chemotherapy; Phase 1 results showed positive safety and a 1.07 kg weight difference vs placebo (p=0.0195). 710GO is an oral dual MC3R/MC4R agonist for general obesity treatment, with Phase 1 in healthy overweight/obese volunteers planned for the first half of 2026, and preclinical primate data showing 11.7% body weight reduction with minimal lean mass loss and only 1.1% weight rebound seven weeks post-treatment. In March 2026, Endevica spun out Kalohexis to advance the obesity and metabolic disease portfolio, with Endevica's leadership team leading the new entity.

Endevica Bio is pre-revenue with no commercial products. Revenue is expected to materialize post-FDA approval through pharmaceutical partnerships or direct sales. To date the company has raised approximately $14 million cumulatively, including a $10 million Series B in January 2023, plus earlier non-dilutive funding from the National Cancer Institute and Centennial Investors. The go-to-market motion relies on conducting clinical trials in partnership with CROs (e.g., WuXi Clinical for the Phase 2 program) and eventually commercializing through pharma partnerships or direct sales channels targeting oncology practices (cachexia) and obesity-treating providers. The company maintains a content-driven marketing approach emphasizing peer-reviewed publication and disease awareness, targeting an addressable market projected to reach USD 4.1 billion by 2032 for the cancer cachexia segment alone.

Name

Endevica Bio

Legal name

Endevica Bio, Inc.

Website

https://endevicabio.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Endevica Bio is a clinical-stage biotechnology company developing first-in-class peptide therapeutics that target the melanocortin system to treat cancer cachexia (mifomelatide, Phase 2) and obesity (710GO, Phase 1 planned 2026). The company is pre-revenue and headquartered in Northbrook, Illinois.

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals / Peptide therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Ophthalmology Biosimilars (HLAAAHAH)

akta.pro secondary industries

Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Peptide therapeutics
• Clinical-stage biopharmaceuticals
• Cancer cachexia treatment
• Metabolic disease drugs
• Melanocortin receptor modulators

Headquarters

HQ city

Northbrook

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biotechnology company. Revenue will be generated through commercialization of drug candidates upon regulatory approval, potentially through partnerships with pharmaceutical companies or direct sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide drug candidates that modulate the melanocortin system (MC3R/MC4R) for metabolic diseases. Its pipeline includes TCMCB07 (mifomelatide), a dual MC3R/MC4R antagonist peptide in Phase 2 development for preventing and treating cancer cachexia, and 710GO, an oral dual MC3R/MC4R agonist in preclinical development for general obesity treatment. Both candidates leverage a proprietary platform for designing peptides that cross the blood-brain barrier.

Product overview

Endevica Bio is a clinical-stage biotechnology company developing first-in-class synthetic peptide drug candidates that modulate the melanocortin system for metabolic diseases. The company's pipeline includes two clinical-stage drug candidates: TCMCB07 (mifomelatide), a dual MC3R/MC4R antagonist peptide in Phase 2 development for preventing and treating cancer cachexia; and 710GO, an oral dual MC3R/MC4R agonist in Phase 1 development for general obesity treatment. Both candidates leverage the melanocortin system's role in regulating metabolic homeostasis, appetite, and body weight.

Differentiator

Problem solved

Functional benefit

Products and services

• TCMCB07 (mifomelatide) A dual melanocortin-3 and -4 receptor (MC3R/MC4R) antagonist peptide drug candidate in clinical development for the treatment and prevention of cachexia in cancer patients undergoing chemotherapy. Designed to cross the blood-brain barrier and modulate the body's behavioral and metabolic response to chronic illness, preserving lean mass and fat mass.
• 710GO An oral dual MC3R/MC4R agonist peptide designed to activate the melanocortin system to induce weight loss for treatment of general obesity. Demonstrated preclinical efficacy in obese nonhuman primates with limited lean mass loss and minimal weight rebound after treatment cessation.

Quantifiable outcome

• 11.7% body weight reduction over 15 weeks in obese nonhuman primates with 710GO monotherapy
• +5 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• KalohexiscoreStrategic or Co-development Partner · 1 March 2026Kalohexis was spun out from Endevica Bio in March 2026 to advance the clinical development of melanocortin drug candidates for obesity and metabolic diseases. The Endevica Bio leadership team leads the newly spun-out company. Kalohexis is advancing 710GO for obesity and mifomelatide for cachexia.
• WuXi ClinicalcoreStrategic or Co-development Partner · 1 April 2025WuXi Clinical is serving as the clinical research partner for Endevica Bio's Phase 2 trial of TCMCB07. The partnership enables the trial to be conducted across 20 sites with 100 patients diagnosed with stage 4 metastatic colorectal cancer.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Rhythm Pharmaceuticals: Direct melanocortin-system peer developing setmelanotide (an MC4R agonist) for rare genetic forms of obesity. Most directly comparable company given the shared MC-pathway mechanism and metabolic-disease focus.
• Palatin Technologies: Melanocortin-peptide specialist (bremelanotide for HSDD, MC1R/MC4R programs). Comparable peptide platform targeting melanocortin receptors and small team characteristic of clinical-stage biotechs.
• Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company focused on endocrine/metabolic diseases (paltusotine for acromegaly). Comparable peptide modality, similar clinical-stage profile, and overlapping therapeutic area in endocrinology and metabolism.
• Zealand Pharma: Peptide therapeutics company developing dasiglucagon, glepaglutide, and other peptide drugs for metabolic and rare diseases. Direct comparison on peptide platform technology and metabolic indication strategy.
• Actimed Therapeutics: Clinical-stage company developing S-pindolol for cancer cachexia and other muscle-wasting conditions. Closest direct competitor in the cachexia indication that TCMCB07 targets.

Emerging players

• BioAge Labs: Clinical-stage biotech developing therapies for metabolic diseases of aging, including obesity and related conditions. Comparable metabolic-disease focus with overlapping patient populations.
• Madrigal Pharmaceuticals: Clinical-to-commercial biotech in metabolic liver disease (resmetirom for MASH). Comparable profile of a focused metabolic-disease company with first-in-class positioning and similar regulatory pathway dynamics.
• Soleno Therapeutics: Clinical-stage biotech developing diazoxide choline controlled-release for hyperphagia in Prader-Willi syndrome. Comparable small-cap, single-asset clinical-stage biotech focused on a rare metabolic disorder with high unmet need.

Broad incumbents

• Eli Lilly: Broad incumbent in obesity via tirzepatide and retatrutide (GLP-1/GIP/glucagon agonists). Represents the dominant commercial competitor to melanocortin-based obesity therapies like 710GO, and a likely acquirer or partner candidate.
• Novo Nordisk: Global GLP-1 leader (semaglutide) in obesity and type 2 diabetes. The dominant incumbent whose franchise success defines the competitive context for any novel obesity mechanism including 710GO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/kalohexis
• LinkedInlinkedin.com/company/endevicabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Endevica Bio